FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3185581530> ?p ?o ?g. }

• W3185581530 endingPage "106408" @default.
• W3185581530 startingPage "106408" @default.
• W3185581530 abstract "Continuous infusion (CI) piperacillin/tazobactam is frequently used to treat infections in very elderly patients. This study aimed to conduct a population pharmacokinetic analysis of CI piperacillin/tazobactam, and to identify optimal dosages for safe and effective probability of target attainment (PTA) against Enterobacterales and Pseudomonas aeruginosa. Non-linear mixed-effects modelling was performed with Pmetrics. Monte Carlo simulations assessed the steady-state concentration (Css) of increasing piperacillin/tazobactam regimens (from 2.25 to 18 g daily by continuous infusion). Permissible doses were defined as those associated with <10% probability of Css >157.2 mg/L. PTA at the pharmacodynamic targets of free plasma steady-state concentration (fCss)/minimum inhibitory concentration (MIC) ≥1 and ≥4 and cumulative fraction of response (CFR) against EUCAST MIC distribution were also calculated. A total of 141 patients (median age 85 years) provided 217 plasma piperacillin Css. Most patients (55.2%) had hospital-acquired pneumonia and intra-abdominal infections. A one-compartment pharmacokinetic model with parallel linear and Michaelis-Menten elimination best described piperacillin data. Creatinine clearance (CLCR) was the covariate retained by the model. Pharmacokinetic estimates were 6.05 L/h for clearance and 3.39 mg/L for the Michaelis-Menten constant. Permissible doses were up to 4.5, 9, 11.25 and 13.5 g daily by continuous infusion for patients with CLCR of 0-19, 20-39, 40-59 and 60-79 mL/min/1.73 m2, respectively. At the clinical breakpoint of 8 mg/L, the permissible doses only achieved optimal PTA for fCss/MIC ≥1 in patients with CLCR 20-79 mL/min/1.73 m2. Optimal CFRs with the permissible doses were only attained against Escherichia coli and Proteus mirabilis. Permissible dosages and CLCR should be considered for prescribing CI piperacillin/tazobactam in very elderly patients." @default.
• W3185581530 created "2021-08-02" @default.
• W3185581530 creator A5060209118 @default.
• W3185581530 creator A5061400936 @default.
• W3185581530 creator A5071687756 @default.
• W3185581530 creator A5082781133 @default.
• W3185581530 date "2021-10-01" @default.
• W3185581530 modified "2023-10-02" @default.
• W3185581530 title "Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa" @default.
• W3185581530 cites W1748671778 @default.
• W3185581530 cites W1984031356 @default.
• W3185581530 cites W1985551650 @default.
• W3185581530 cites W1989436589 @default.
• W3185581530 cites W2021298363 @default.
• W3185581530 cites W2024865137 @default.
• W3185581530 cites W2087285375 @default.
• W3185581530 cites W2098667568 @default.
• W3185581530 cites W2105689903 @default.
• W3185581530 cites W2111421292 @default.
• W3185581530 cites W2121189212 @default.
• W3185581530 cites W2121282317 @default.
• W3185581530 cites W2143024482 @default.
• W3185581530 cites W2155965977 @default.
• W3185581530 cites W2167943565 @default.
• W3185581530 cites W2298261704 @default.
• W3185581530 cites W2315132647 @default.
• W3185581530 cites W2316297039 @default.
• W3185581530 cites W2584388311 @default.
• W3185581530 cites W2585585846 @default.
• W3185581530 cites W2613345353 @default.
• W3185581530 cites W2735133396 @default.
• W3185581530 cites W2735527391 @default.
• W3185581530 cites W2752537900 @default.
• W3185581530 cites W2778135811 @default.
• W3185581530 cites W2793390003 @default.
• W3185581530 cites W2892368225 @default.
• W3185581530 cites W2893087473 @default.
• W3185581530 cites W2915964033 @default.
• W3185581530 cites W2948467125 @default.
• W3185581530 cites W2963222371 @default.
• W3185581530 cites W2965406147 @default.
• W3185581530 cites W2970215031 @default.
• W3185581530 cites W2971035875 @default.
• W3185581530 cites W3005700774 @default.
• W3185581530 cites W3015674697 @default.
• W3185581530 cites W3064121625 @default.
• W3185581530 doi "https://doi.org/10.1016/j.ijantimicag.2021.106408" @default.
• W3185581530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34314808" @default.
• W3185581530 hasPublicationYear "2021" @default.
• W3185581530 type Work @default.
• W3185581530 sameAs 3185581530 @default.
• W3185581530 citedByCount "10" @default.
• W3185581530 countsByYear W31855815302022 @default.
• W3185581530 countsByYear W31855815302023 @default.
• W3185581530 crossrefType "journal-article" @default.
• W3185581530 hasAuthorship W3185581530A5060209118 @default.
• W3185581530 hasAuthorship W3185581530A5061400936 @default.
• W3185581530 hasAuthorship W3185581530A5071687756 @default.
• W3185581530 hasAuthorship W3185581530A5082781133 @default.
• W3185581530 hasConcept C111113717 @default.
• W3185581530 hasConcept C112705442 @default.
• W3185581530 hasConcept C126322002 @default.
• W3185581530 hasConcept C176947019 @default.
• W3185581530 hasConcept C2777637488 @default.
• W3185581530 hasConcept C2777858937 @default.
• W3185581530 hasConcept C2778193466 @default.
• W3185581530 hasConcept C2778266534 @default.
• W3185581530 hasConcept C2908647359 @default.
• W3185581530 hasConcept C3019249092 @default.
• W3185581530 hasConcept C42219234 @default.
• W3185581530 hasConcept C501593827 @default.
• W3185581530 hasConcept C523546767 @default.
• W3185581530 hasConcept C54355233 @default.
• W3185581530 hasConcept C71924100 @default.
• W3185581530 hasConcept C86803240 @default.
• W3185581530 hasConcept C89423630 @default.
• W3185581530 hasConcept C99454951 @default.
• W3185581530 hasConceptScore W3185581530C111113717 @default.
• W3185581530 hasConceptScore W3185581530C112705442 @default.
• W3185581530 hasConceptScore W3185581530C126322002 @default.
• W3185581530 hasConceptScore W3185581530C176947019 @default.
• W3185581530 hasConceptScore W3185581530C2777637488 @default.
• W3185581530 hasConceptScore W3185581530C2777858937 @default.
• W3185581530 hasConceptScore W3185581530C2778193466 @default.
• W3185581530 hasConceptScore W3185581530C2778266534 @default.
• W3185581530 hasConceptScore W3185581530C2908647359 @default.
• W3185581530 hasConceptScore W3185581530C3019249092 @default.
• W3185581530 hasConceptScore W3185581530C42219234 @default.
• W3185581530 hasConceptScore W3185581530C501593827 @default.
• W3185581530 hasConceptScore W3185581530C523546767 @default.
• W3185581530 hasConceptScore W3185581530C54355233 @default.
• W3185581530 hasConceptScore W3185581530C71924100 @default.
• W3185581530 hasConceptScore W3185581530C86803240 @default.
• W3185581530 hasConceptScore W3185581530C89423630 @default.
• W3185581530 hasConceptScore W3185581530C99454951 @default.
• W3185581530 hasIssue "4" @default.
• W3185581530 hasLocation W31855815301 @default.
• W3185581530 hasLocation W31855815302 @default.

• next